Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial

被引：0

作者：

Wolisnky, J. S. ^{[1
]}

Brochet, B. ^{[2
]}

Montalban, X. ^{[3
,4
]}

Naismith, R. T. ^{[5
]}

Manfrini, M. ^{[6
]}

Garas, M. ^{[6
]}

Villoslada, P. ^{[7
]}

Model, F. ^{[6
]}

Hubeaux, S. ^{[6
]}

Kappos, L. ^{[8
]}

Hauser, S. L. ^{[9
]}

机构：

[1] UTHealth, McGovern Med Sch, Houston, TX USA

[2] Univ Bordeaux, Bordeaux, France

[3] Univ Toronto, Div Neurol, Toronto, ON, Canada

[4] Vall dHebron Univ Hosp, Barcelona, Spain

[5] Washington Univ, Sch Med, St Louis, MO USA

[6] F Hoffmann La Roche Ltd, Basel, Switzerland

[7] Genentech Inc, San Francisco, CA 94080 USA

[8] Univ Basel, Univ Hosp Basel, Basel, Switzerland

[9] Univ Calif San Francisco, San Francisco, CA 94143 USA

来源：

MULTIPLE SCLEROSIS JOURNAL | 2018年 / 24卷

基金：

新加坡国家研究基金会;

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P910

引用

页码：490 / 491

页数：2

共 50 条

[31] Evaluation of No Evidence of Progression or Active Disease (NEPAD) in Patients with Primary Progressive Multiple Sclerosis in the ORATORIO Trial [J].

Wolinsky, Jerry ;

Montalban, Xavier ;

Kappos, Ludwig ;

Hauser, Stephen ;

Giovannoni, Gavin ;

de Seze, Jerome ;

Bar-Or, Amit ;

Masterman, Donna ;

Bemasconi, Corrado ;

Wei, Wei ;

Garren, Hideki ;

Chin, Peter ;

Belachew, Shibeshih ;

Arnold, Douglas .

NEUROLOGY, 2017, 88

[32] Interim Analysis of Open-Label Extension Studies of Sustained Release Fampridine in Patients with Multiple Sclerosis [J].

Goodman, Andrew D. ;

Brown, Ted R. ;

Edwards, Keith R. ;

Schapiro, Randall T. ;

Marinucci, Lawrence N. ;

Cohen, Ron ;

Blight, Andrew R. .

NEUROLOGY, 2010, 74 (09) :A101-A101

[33] Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis - results of the placebo-controlled, double-blind, Phase III ORATORIO study [J].

Montalban, X. ;

Hemmer, B. ;

Rammohan, K. ;

Giovannoni, G. ;

de Seze, J. ;

Bar-Or, A. ;

Arnold, D. L. ;

Sauter, A. ;

Kakarieka, A. ;

Masterman, D. ;

Chin, P. ;

Garren, H. ;

Wolinsky, J. .

MULTIPLE SCLEROSIS JOURNAL, 2015, 21 :781-782

[34] Efficacy and Safety of Ocrelizumab in Primary Progressive Multiple Sclerosis: Results of the Phase III Double-Blind, Placebo-Controlled ORATORIO Study [J].

Montalban, Xavier ;

Hemmer, Bernhard ;

Rammohan, Kottil ;

Giovannoni, Gavin ;

De Seze, Jerome ;

Bar-Or, Amit ;

Arnold, Douglas ;

Sauter, Annette ;

Masterman, Donna ;

Fontoura, Paulo ;

Garren, Hideki ;

Chin, Peter ;

Wolinsky, Jerry .

NEUROLOGY, 2016, 86

[35] Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions [J].

Derfuss, T. ;

Weber, M. S. ;

Hughes, R. ;

Wang, Q. ;

Sauter, A. ;

Koendgen, H. ;

Hauser, S. L. ;

Bar-Or, A. ;

Hartung, H. -P. .

MULTIPLE SCLEROSIS JOURNAL, 2019, 25 :20-21

[36] Patient-reported outcomes in the phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis [J].

de Seze, J. ;

Montalban, X. ;

McDougall, F. ;

Sauter, A. ;

Deol-Bhullar, G. ;

Wolinsky, J. .

MULTIPLE SCLEROSIS JOURNAL, 2016, 22 :677-678

[37] Patient-reported outcomes in the phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis [J].

de Seze, Jerome ;

Montalban, Xavier ;

McDougall, Fiona ;

Julian, Laura ;

Sauter, Annette ;

Deol-Bhullar, Gurpreet ;

Wolinsky, Jerry .

MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (01) :84-84

[38] Results of an open-label extension trial of sativex (THC:CBD) in patients with multiple sclerosis and symptoms of spasticity [J].

Collin, C. ;

Serpell, M. ;

Potts, R. .

MULTIPLE SCLEROSIS, 2007, 13 :S129-S129

[39] Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the random-ised, placebo-controlled, phase 3 trial (vol 19, pg 998, 2020) [J].

Wolinsky, J. S. ;

Arnold, D. L. ;

Brochet, B. .

LANCET NEUROLOGY, 2021, 20 (01) :E1-E1

[40] Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension [J].

Kapoor, Raja ;

Ho, Pei-Ran ;

Campbell, Nolan ;

Chang, Ih ;

Deykin, Aaron ;

Forrestal, Fiona ;

Lucas, Nisha ;

Yu, Bei ;

Arnold, Douglas L. ;

Freedman, Mark ;

Goldman, Myia D. ;

Hartung, Hans-Peter ;

Kubala Havrdova, Eva ;

Jeffery, Douglas ;

Miller, Aaron ;

Sellebjerg, Finn ;

Cadavid, Diego ;

Mikol, Dan ;

Steiner, Deborah .

LANCET NEUROLOGY, 2018, 17 (05) :405-415

← 1 2 3 4 5 →